京新藥業(002020.SZ):擬以2.108億元收購胡慶餘堂6%股權
格隆匯11月8日丨京新藥業(002020.SZ)公佈,公司擬以自有資金2.108億元收購新昌元金健康產業投資合夥企業(有限合夥)(“元金健康”)持有的杭州胡慶餘堂醫藥控股有限公司(“胡慶餘堂”或“目標公司”)6%股權。
杭州胡慶餘堂醫藥控股有限公司是杭州胡慶餘堂集團有限公司的重要控股子公司,整合了集團醫藥產業的優質資源。通過本次股權轉讓收購,公司中藥產業佈局進一步拓寬,深化優秀中藥企業的交流合作、互助共贏,符合公司已有中藥產業發展規劃、有利於進一步提升公司總體經營業績,實現公司的可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.